Bryan Medical Center Offers Newest Advancement in Detecting Prostate Cancer
MRI-ultrasound fusion biopsy latest prostate cancer diagnostic tool
Fusion biopsy for prostate cancer has come to Bryan Medical Center – one of a small number of U.S. hospitals to perform the new technology. Fusion biopsy combines two standard imaging tests: Magnetic resonance imaging (MRI) and ultrasound, to create this major advancement in detecting prostate cancer.
Bryan Health recently combined forces with urologic surgeon Jonathan Henning, MD, and his partners at Urology, P.C.; diagnostic radiologist Eric Williams, MD, of the Lincoln Radiology Group; and radiation oncologist Joseph Kam Chiu, MD, of Southeast Nebraska Cancer Center, to bring this new technology to Lincoln.
“We wanted to bring a more sensitive diagnostic tool to Lincoln, especially for men with low-risk prostate cancer, for whom the standard treatment is medical surveillance rather than surgery,” says Dr. Henning.
Fusion biopsy enhances prostate cancer detection by combining detailed, three-dimensional MRI images with real-time ultrasound images of the prostate, allowing very specific targeting of areas of the prostate that are most likely to contain cancer in each patient’s case. Patients who are good candidates for fusion biopsy are:
• Those with high blood prostate-specific antigen (PSA) levels
• Those who have undergone standard ultrasound-guided random needle biopsy to screen for prostate cancer
If a standard biopsy is negative, doctors continue to screen patients carefully to detect prostate cancer quickly if it develops later. One such patient is Darrell Bolles of Lincoln, who was diagnosed with prostate cancer following a fusion biopsy.
“The MRI-ultrasound fusion biopsy was the way to go,” says Darrell. Urologic surgeon Don Henslee, MD, “was very good at explaining everything as he went along, and the whole procedure took just 30 minutes start to finish,” Darrell says. “And there was little discomfort, no bleeding, and I didn’t have to go to the surgery suite or be under anesthesia, which was great.”
“There’s very clear evidence that fusion biopsy can find aggressive prostate cancer in 25-30 percent of patients for whom the severity of disease was underestimated by a previous standard biopsy,” Dr. Henning says. “We are seeing that in some cases fusion biopsy can be nearly twice as sensitive in finding prostate cancer than standard biopsy.”
Dr. Henning and his colleagues also emphasize the importance of prostate cancer screening in protecting men’s health.
“The take-home message is that 250,000 men are diagnosed with prostate cancer in the United States every year, and though it’s often low-risk, 30,000 men actually die of this disease each year,” Dr. Henning says. “Talk with your doctor about how and when to screen, and the pros and cons of prostate screening for your situation.”